Area of research
Pathology and Forensic Medicine · Oncology
Research interest
Research interests include Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, and Cutaneous lymphoproliferative disorders research.
Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma.
Naïve CD4<sup>+</sup> T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.
Investigating Associations Between Psychological Distress and Changes in Peripheral Blood Monocytes in Patients With CLL/SLL Managed With Active Surveillance.
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma
Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers
Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing.
Genomic Features of Newly Diagnosed Large B-cell Lymphoma with or without Subsequent Disease Progression.
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
Outcomes of patients with <scp>limited‐stage</scp> plasmablastic lymphoma: A <scp>multi‐institutional</scp> retrospective study
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study.
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective study.
Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells
Central Line-Associated Bloodstream Infection in Patients With Hematologic Malignancy Receiving Parenteral Nutrition.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022
Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Willingness to Travel for Cellular Therapy: The Influence of Follow-Up Care Location, Oncologist Continuity, and Race.
ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses.
Patterns of immune checkpoint protein expression in MYC-overexpressing aggressive B-cell non-Hodgkin lymphomas.
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020